Ilexgenin A

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ilexgenin A 是一种新型五环三萜类化合物，是从海南冬青 (Ilex hainanensis Merr) 叶中提取的化合物。通过调节血脂参数、降低动脉粥样硬化相关指标、抑制炎性细胞因子分泌和主要器官病理改变等一系列作用诱导载脂蛋白E缺陷小鼠。

Ilexgenin A is a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis MerrIlexgenin A (IA), a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis Merr.treatment with IA attenuated atherosclerosis in high-fat diet-induced apolipoprotein E deficient mice via a series of effects involving regulation of lipid parameters, decrease of atherosclerosis-related indexes, inhibition of inflammatory cytokines secretion and pathological changes of main organs.?The underlying mechanism of IA was investigated on oxidized low-density lipoprotein (Ox-LDL)-induced THP-1 cells.?Pre-treatment with IA decreased active inflammation cytokines involving interleukin-6 (IL-6), IL-1 and tumor necrosis factor-α (TNF-α) expression in a concentration-dependent manner.IA inhibited the phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), IKKα phosphorylation and NF-κB activity induced by Ox-LDL.?Overall, these findings define IA as a novel drug candidate for anti-atherosclerotic therapy.(In Vitro):Ilexgenin A (0~100 μM; 24 hours; HT 29 and HCT 116 cells) effectively decreases cell viability in HT 29 and HCT 116 cells.Ilexgenin A (12.5~50 μM; 24 hours; HT 29 cells) downregulates the expression of SREBP-1, inhibits the translocation of SREBP-1 to the nucleus and decreases the content of TG.Ilexgenin A (12.5~50 μM; HT 29 and HCT 116 cells) induces cell cycle arrest at G1 phase in colon cancer cells.Ilexgenin A (12.5~50 μM; 24 hours; HCT 116 cells) modulates lipid metabolism. Ilexgenin A (50 μM; 24 hours; HT 29 and HCT 116 cells) regulates SREBP-1 by inhibiting HIF1α.Ilexgenin A inhibits fatty acids synthesis.(In Vivo):Ilexgenin A (20 mg/kg) ameliorates the AOM/DSS induced carcinogenesis. Ilexgenin A can regulate lipid metabolism. Ilexgenin A decreases the expression of SREBP-1 and HIF 1α in AOM/DSS mice.

Ilexgenin A (0~100 μM; 24 hours; HT 29 and HCT 116 cells) effectively decreases cell viability in HT 29 and HCT 116 cells.Ilexgenin A (12.5~50 μM; 24 hours; HT 29 cells) downregulates the expression of SREBP-1, inhibits the translocation of SREBP-1 to the nucleus and decreases the content of TG.Ilexgenin A (12.5~50 μM; HT 29 and HCT 116 cells) induces cell cycle arrest at G1 phase in colon cancer cells.Ilexgenin A (12.5~50 μM; 24 hours; HCT 116 cells) modulates lipid metabolism. Ilexgenin A (50 μM; 24 hours; HT 29 and HCT 116 cells) regulates SREBP-1 by inhibiting HIF1α.Ilexgenin A inhibits fatty acids synthesis. Cell Viability Assay Cell Line:HT 29 and HCT 116 cells Concentration:0~100 μM Incubation Time:24 hours Result:Effectively decreased cell viability in HT 29 and HCT 116 cells.Western Blot Analysis Cell Line:HT 29 cells Concentration:12.5~50 μMIncubation Time:24 hours Result:Downregulated the expression of SREBP-1. RT-PCRCell Line:HT 29 cells Concentration:12.5~50 μM Incubation Time:24 hours Result:Decreased the content of TG.Immunofluorescence Cell Line:HT 29 cells Concentration:12.5~50 μM Incubation Time:24 hours Result:Inhibited the translocation of SREBP-1 to the nucleus.

Ilexgenin A (20 mg/kg) ameliorates the AOM/DSS induced carcinogenesis. Ilexgenin A can regulate lipid metabolism. Ilexgenin A decreases the expression of SREBP-1 and HIF 1α in AOM/DSS mice.

——

Apoptosis

IL Receptor

IL Receptor|TNF-α

——

——

108524-94-3

502.69

C30H46O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (198.93 mM)

CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C(=O)O)O)C)C)C2C1(C)O)C)C(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years